Tag Archives: chronic inflammatory diseases

Fresenius Kabi Secures Global Rights to PB016 Vedolizumab Biosimilar from Polpharma Biologics

(IN BRIEF) Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the Middle East and North Africa—once approved. Vedolizumab treats Crohn’s disease and ulcerative colitis, and PB016 references Takeda’s Entyvio®. The transaction … Read the full press release

Sanofi to provide an update on its Immunology strategy at its Immunology Investor Event

(PRESS RELEASE) PARIS, 29-Mar-2022 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced that the company will provide an update on its Immunology strategy at its Immunology Investor Event, which is taking place … Read the full press release